TissueTech Revenue and Competitors
Estimated Revenue & Valuation
- TissueTech's estimated annual revenue is currently $47.9M per year.
- TissueTech's estimated revenue per employee is $155,000
- TissueTech's total funding is $110M.
- TissueTech has 309 Employees.
- TissueTech grew their employee count by -6% last year.
TissueTech Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is TissueTech?
TissueTech, Inc. is a Biotechnology company headquartered in Miami, FL. TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. TissueTech offers its portfolio of amniotic membrane and umbilical cord-based tissue and device products through its commercial entities: BioTissue, Inc: the industry leader in regenerative tissue therapies for ocular surface diseases and disorders. Amniox Medical: a leading technology provider to the musculoskeletal and wound care markets.keywords:N/A
Number of Employees
Employee Growth %
Chronic Wounds Clinical and Non-Clinical Studies, Emerging Products, and Treatment Algorithm | Key Companies- Tissue Tech, Amniox Medical,...
Satellite Bio goes into orbit with $110M VC funding for bioengineered tissue tech. Hand holding dollar sign. April 20, 2022. By Richard Staines.
Jun 26 2019 EW Healthcare Partners Managing Director Martin Sutter and Former Medtronic CEO Bill Hawkins join TissueTech Board of Directors (PRWEB) MIAMI, Florida—TissueTech, Inc., the pioneer in regenerative medicine utilizing human umbilical cord and amniotic membrane, today announced the cl ...
TissueTech, Inc., a Miami, FL-based regenerative medicine company utilizing human umbilical cord and amniotic membrane, closed an $82.25m in Series C equity financing. The round was led by EW Healthcare Partners (formerly Essex Woodlands) with continuous investments from Ballast Point Ventures. ...
TissueTech, Inc., a Miami, FL-based regenerative tissue engineering company, completed a $15m Series B financing. Backers included River Cities Capital Funds and Ballast Point Ventures. Led by Amy Tseng, CEO., and Dr. Scheffer Tseng, MD, PhD, Chairman and Chief Scientific Officer, TissueTech o ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|